Welcome to Flow Pharma Inc.

Page Loading...

Menu

Vaccination by Inhalation

 

X-rays of COVID-19 exposed monkeys.

The left monkey was treated with FLOVID-20.

 

 

Under Development, FDA approval required.


FLOVID-20

Treatment for new COVID-19 infections. Administered by inhaler.

The mutation threat is growing. FLOVID-20 is designed to treat all known variants.

Under Development, FDA Approval Required


The FlowVax Platform

A new kind of immune system therapy (immunotherapy).

Medicines that precisely treat cancer and viral disease with minimal side effects.


Stable Dry Powder

Multiple Delivery Pathways

  • For Virus – inhalation, intramuscular

  • For Cancer – intranodal, intramuscular

Quick disease-specific therapy creation. Rapid high-volume production capability.


About Us

We are Flow Pharma.

The Science

The research behind the solution.

Latest News

Stay up to date.

Investor Relations

Contact our team.
blob-1
blob-2
Our Mission

Flow Pharma engineers and manufactures state-of-the-art medicines.

Our unique patented delivery system and biotechnology are ideally suited for curative intervention in cancer and viral disease.

Subscribe to Flow Pharma Updates




FLOVID-20

COVID-19

A inhaled treatment to prevent COVID-19 disease in both virus-exposed and healthy patient populations.

Learn More

FlowVax Ebola & Marburg

Ebola, Marburg

Marburg is a weaponized Ebola-like virus. By stimulating T-cells to target this virus, long-lasting infection prevention is attainable.

Learn More

FlowVax BreastCA

Cancer

A revolutionary T-cell biomedicine that provides new hope for those with treatment-resistant, triple-negative breast cancer.

Learn More

FlowVax HPV

Cancer, HPV

A targeted T-cell immunotherapy for HPV-induced squamous cell carcinoma of the head, neck, and cervix.

Learn More
View All Products